PTAB Upholds ImmunoGen's Breast Cancer Drug Patent
The Patent Trial and Appeal Board on Tuesday ruled that Phigenix Inc. fell short of proving that claims of ImmunoGen Inc.'s patent covering the breast cancer treatment Kadcyla were unpatentable....To view the full article, register now.
Already a subscriber? Click here to view full article